28.02
-0.59 (-2.06%)
| Previous Close | 28.61 |
| Volume | 804,113 |
| Price / Sales | 14.42 |
| Price / Book | 31.95 |
| 52 Weeks Range |
| Profit Margin | -74.84% |
| Operating Margin (TTM) | -56.45% |
| Diluted EPS (TTM) | -0.950 |
| Quarterly Revenue Growth (YOY) | 25.20% |
| Total Debt/Equity (MRQ) | 115.90% |
| Current Ratio (MRQ) | 2.92 |
| Operating Cash Flow (TTM) | -85.34 M |
| Levered Free Cash Flow (TTM) | -21.40 M |
| Return on Assets (TTM) | -15.05% |
| Return on Equity (TTM) | -61.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Adaptive Biotechnologies Corpor | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -3.0 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | -0.38 |
|
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 2.35% |
| % Held by Institutions | 98.36% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BOBULSKY SUSAN | - | 26.68 | -1,195 | -31,883 |
| Aggregate Net Quantity | -1,195 | |||
| Aggregate Net Value ($) | -31,883 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 26.68 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BOBULSKY SUSAN | Officer | 15 Sep 2026 | Automatic sell (-) | 1,195 | 26.68 | 31,883 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |